Aspirin in the prevention of cardiovascular disease: a review
JIANG Yuchen1, GAO Qian2
1. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong 999077, China; 2. Anhui Medical University, Hefei, Anhui 230032, China
Abstract：Aspirin (ASA) is widely used for primary and secondary prevention of cardiovascular disease (CVD), but its strategy of application is highly controversial. Meanwhile, in terms of ASA prevention strategies for CVD, countries around the world are different. The United States is becoming increasingly cautious, while the European Union tends to focus on the benefits of ASA clinical use. China is concerned about the effectiveness of ASA in preventing CVD in the elderly. This article reviews relevant literature published domestically and internationally from 2005 to 2024 for the application of ASA in CVD prevention, ASA prevention strategies for CVD in main countries and the application of ASA in special groups such as chronic disease patients, which provides a basis for improving ASA prevention strategies for CVD and standardizing clinical application of ASA in China.
[1] BENJAMIN E J,VIRANI S S,CALLAWAY C W,et al.Heart disease and stroke statistics-2018 update:a report from the American Heart Association[J/OL].Circulation,2018,137(12)[2024-03-03].https://doi.org/10.1161/CIR.0000000000000558. [2] ROTH G A,MENSAH G A,JOHNSON C O,et al.Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 study[J].J Am Coll Cardiol,2020,76(25):2982-3021. [3] LUEPKER R V,OLDENBURG N C,MISIALEK J R,et al.Aspirin use and misuse for the primary prevention of cardiovascular diseases[J].Am J Prev Med,2021,60(4):513-519. [4] HYBIAK J,BRONIAREK I,KIRYCZYŃSKI G,et al.Aspirin and its pleiotropic application[J/OL].Eur J Pharmacol,2020,866[2024-03-03].https://doi.org/10.1016/j.ejphar.2019.172762. [5] SINGAL A K,KARTHIKEYAN G.Aspirin for primary prevention:is this the end of the road?[J].Indian Heart J,2019,71(2):113-117. [6] HAMBERG M,SVENSSON J,SAMUELSSON B.Thromboxanes:a new group of biologically active compounds derived from prostaglandin endoperoxides[J].Proc Natl Acad Sci USA,1975,72(8):2994-2998. [7] PATRONO C,GARCÍA RODRÍGUEZ L A,LANDOLFI R,et al.Low-dose aspirin for the prevention of atherothrombosis[J].N Engl J Med,2005,353(22):2373-2383. [8] ZHENG S L,RODDICK A J.Association of aspirin use for primary prevention with cardiovascular events and bleeding events:a systematic review and meta-analysis[J].JAMA,2019,321(3):277-287. [9] DIETRICH E,DAVIS K.A statin a day to keep the doctor away? Comparing aspirin and statins for primary prevention of cardiovascular disease[J].Ann Pharmacother,2014,48(9):1238-1241. [10] NAVARATNAM K,ALFIREVIC A,ALFIREVIC Z.Low dose aspirin and pregnancy:how important is aspirin resistance?[J].BJOG,2016,123(9):1481-1487. [11] MENSAH G A,ROTH G A,FUSTER V.The global burden of cardiovascular diseases and risk factors:2020 and beyond[J].J Am Coll Cardiol,2019,74(20):2529-2532. [12] RABER I,MCCARTHY C P,VADUGANATHAN M,et al.The rise and fall of aspirin in the primary prevention of cardiovascular disease[J].Lancet,2019,393(10186):2155-2167. [13] CHALUPKA S.Using aspirin to prevent cardiovascular disease in adults[J].AAOHN J,2009,57(7):300. [14] PATRONO C,BAIGENT C.Role of aspirin in primary prevention of cardiovascular disease[J].Nat Rev Cardiol,2019,16(11):675-686. [15] ANGIOLILLO D J,CAPODANNO D.Aspirin for primary prevention of cardiovascular disease in the 21st century:a review of the evidence[J].Am J Cardiol,2021,144(Suppl.1):S15-S22. [16] SELAK V,JACKSON R,POPPE K,et al.Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?[J].N Z Med J,2018,131(1484):19-25. [17] VAN'T HOF J R,DUVAL S,WALTS A,et al.Contemporary primary prevention aspirin use by cardiovascular disease risk:impact of US Preventive Services Task Force recommendations,2007-2015:a serial,cross-sectional study[J].J Am Heart Assoc,2017,6(10):1-11. [18] LIU N,MATHEWS A,SWANSON J,et al.Aspirin use for cardiovascular disease prevention in the uninsured population[J].SAGE Open Med,2020,8:1-7. [19] FRAS Z,SAHEBKAR A,BANACH M.The use of aspirin in contemporary primary prevention of atherosclerotic cardiovascular diseases revisited:the increasing need and call for a personalized therapeutic approach[J].Am J Cardiovasc Drugs,2021,21(2):139-151. [20] ROTHWELL P M,COOK N R,GAZIANO J M,et al.Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose:analysis of individual patient data from randomised trials[J].Lancet,2018,392(10145):387-399. [21] MAGGI P,DE SOCIO G V,CICALINI S,et al.Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs:review of the literature and suggestions for a friendly use[J].AIDS Res Ther,2019,16(1):1-8. [22] AALBERS J.Aspirin in primary prevention:USPSTF recommendations[J].Cardiovasc J Afr,2010,21(3):176. [23] DAVIDSON K W,BARRY M J,MANGIONE C M,et al.Aspirin use to prevent cardiovascular disease:US Preventive Services Task Force recommendation statement[J].JAMA,2022,327(16):1577-1584. [24] MONTGOMERY S,MIEDEMA M D,DODSON J A.Aspirin and statin therapy for primary prevention of cardiovascular disease in older adults[J].Heart,2022,108(14):1090-1097. [25] MAHASE E.US task force advises against low dose aspirin for primary prevention of cardiovascular disease[J/OL].BMJ,2021,375[2024-03-03].https://doi.10.1136/bmj.n2521. [26] SUNDSTRÖM J,HEDBERG J,THURESSON M,et al.Low-dose aspirin discontinuation and risk of cardiovascular events:a Swedish nationwide,population-based cohort study[J].Circulation,2017,136(13):1183-1192. [27] CHRISTENSEN M B,JIMENEZ-SOLEM E,ERNST M T,et al.Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018[J].Sci Rep,2021,11(1):1-8. [28] FERREIRA MOITA C,MARAU G,CORTE-REAL S,et al.Adherence to European guidelines for the use of aspirin in primary health care[J].Rev Port Cardiol,2023,42(4):307-313. [29] ANAND S S,BOSCH J,EIKELBOOM J W,et al.Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease:an international,randomised,double-blind,placebo-controlled trial[J].Lancet,2018,391(10117):219-229. [30] STERPETTI A V,GABRIELE R,SAPIENZA P,et al.Mortality and burden related with aortic aneurysms and dissections.The importance of information and education[J/OL].Curr Probl Cardiol,2024,49(3)[2024-03-03].https://doi.10.1016/j.cpcardiol.2024.102384. [31] LI X Y,SHI Z W,ZHAO D,et al.2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease[J].Chin Med J,2020,133(10):1221-1223. [32] SUN X J,SUN R H,ZHANG L M.The effect of aspirin on the primary prevention of major adverse cardiac and cerebrovascular events in Chinese older adults:a registration study[J].Drugs Aging,2022,39(1):97-106. [33] 中华医学会心血管病学分会,中国康复医学会心脏预防与康复专业委员会,中国老年学和老年医学会心脏专业委员会,等.中国心血管病一级预防指南[J].中华心血管病杂志,2020,48(12):1000-1038. [34] WANG X T,WANG H,ZHENG Q,et al.Outcomes associated with 50 mg/d and 100 mg/d aspirin for the prevention and management of cardiovascular disease in Chinese elderly:single-center interim analysis of a multicenter,prospective,observational study[J].Int J Gen Med,2022,15:7089-7100. [35] AL-SOFIANI M E,DERENBECKER R,QUARTUCCIO M,et al.Aspirin for primary prevention of cardiovascular disease in diabetes:a review of the evidence[J/OL].Curr Diab Rep,2019,19(10)[2024-03-03].https://doi.10.1007/s11892-019-1206-6. [36] CARRICK D,HAIG C,MAZNYCZKA A M,et al.Hypertension,microvascular pathology,and prognosis after an acute myocardial infarction[J].Hypertension,2018,72(3):720-730. [37] DEMPSEY J A,VEASEY S C,MORGAN B J,et al.Pathophysiology of sleep apnea[J].Physiol Rev,2010,90:47-112. [38] LI N F,WEN W,CAI X T,et al.The use of aspirin increases the risk of major adverse cardiac and cerebrovascular events in hypertensive patients with obstructive sleep apnea for the primary prevention of cardiovascular disease:a real-world cohort study[J].J Clin Med,2022,11(23):1-14. [39] GALLAGHER H,DUMBLETON J,MAISHMAN T,et al.Aspirin to target arterial events in chronic kidney disease(ATTACK):study protocol for a multicentre,prospective,randomised,open-label,blinded endpoint,parallel group trial of low-dose aspirin vs.standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease[J].Trials,2022,23(1):1-23.
